ReNeuron Group PLC's (LON:RENE) Michael Hunt speaks to Proactive London's Andrew Scott on the back of its results for the year to the end of March 2020. He says one of the main highlights has been the continuation of the retinal disease clinical study in the US. A recent update showed the treatment to have a “meaningful effect” for all points measured up to 18 months. Hunt adds that one of the key priorities in the year ahead is to build the dataset in that study as it's important for them to continue to show duration of effect at hopefully a higher dose level. ''If we're successful in doing that then that will set us up well for license deals and exploring the greater potential of those hRPC cells''.
ReNeuron's Michael Hunt says key focus now is to build dataset for retinal disease study
Quick facts: ReNeuron Group PLC
Price: 83.31 GBX
Market Cap: £26.56 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE